IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
SHANGHAI, July 31, 2026 /PRNewswire/ — IMPACT Therapeutics (“IMPACT”) (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the “Exclusive Partnership”) with Pharmanovia, a global specialty pharmaceutical company
